Comment from Felix Baldauf-Lenschen

Summary: Altis Labs, Inc. supports the advancement of digital health technologies (DHTs) in clinical investigations, specifically advocating for the inclusion of AI-enabled software that generates digitally-derived endpoints. They request specific guidance on retrospective validation, consortium-based submissions, and clear qualification pathways to reduce regulatory uncertainty for sponsors.